{
    "2021-08-25": [
        [
            {
                "time": "2021-08-25",
                "original_text": "复星医药创新成果落地 复星医药上半年业绩增长强劲",
                "features": {
                    "keywords": [
                        "创新成果",
                        "业绩增长",
                        "复星医药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-26",
                "original_text": "复星医药创新药步入收获期，董事长吴以芳：希望未来打造50亿美元级重磅产品",
                "features": {
                    "keywords": [
                        "创新药",
                        "收获期",
                        "重磅产品"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-27",
                "original_text": "北向资金连续三日加仓累计净买入超百亿，大幅抄底白酒股",
                "features": {
                    "keywords": [
                        "北向资金",
                        "加仓",
                        "白酒股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "白酒"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-28",
                "original_text": "产经报道｜复星医药吴以芳：仿制药下行压力将会持续加大，坚定创新进入无人区",
                "features": {
                    "keywords": [
                        "仿制药",
                        "下行压力",
                        "创新"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "疫苗“添柴”集采“减收” 复星医药将加大创新品种占比",
                "features": {
                    "keywords": [
                        "疫苗",
                        "集采",
                        "创新品种"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-01",
                "original_text": "复星医药A股涨超5% H股涨逾7% 郭广昌：复必泰在正常推进",
                "features": {
                    "keywords": [
                        "A股",
                        "H股",
                        "复必泰"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-02",
                "original_text": "港股异动｜复星医药(2196.HK)涨4.6% 上半年复必泰疫苗收入超5亿元",
                "features": {
                    "keywords": [
                        "港股",
                        "复必泰",
                        "疫苗收入"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-03",
                "original_text": "郭广昌：复必泰审批进展正常 除了疫苗复星医药还有很多好产品",
                "features": {
                    "keywords": [
                        "郭广昌",
                        "复必泰",
                        "审批进展"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-05",
                "original_text": "复星医药：mRNA疫苗国内审批进展正常，首个细胞治疗产品已上市",
                "features": {
                    "keywords": [
                        "mRNA疫苗",
                        "审批进展",
                        "细胞治疗"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-07",
                "original_text": "复星医药拉升 郭广昌称新冠mRNA疫苗复必泰审批进展正常",
                "features": {
                    "keywords": [
                        "复必泰",
                        "审批进展",
                        "拉升"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}